Therapeutic Insights
Filter News
Found 994 articles
-
The decision was based on new analysis run by Biogen in consultation with the FDA of a larger dataset from the trials halted in March. -
The trial met its co-primary endpoints, showing statistically significant and clinically meaningful improvements in overall survival and progression-free survival compared to standard-of-care, Bayer’s Nexavar. -
Janssen Announces U.S. FDA Approval of STELARA® (ustekinumab) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis
10/21/2019
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration's (FDA) approval of STELARA® (ustekinumab) for the treatment of adult patients with moderately to severely active ulcerative colitis.
-
Retrospective Real-World Comparative Analysis Highlights Safety of Vedolizumab and Anti-TNFα Therapies in Biologic-Naïve Patients with Ulcerative Colitis or Crohn’s Disease
10/21/2019
Latest real-world data presented at UEG Week 2019 complements the extensive body of clinical evidence for the gut-selective biologic vedolizumab in biologic-naïve patients with moderately to severely active ulcerative colitis or Crohn’s disease
-
New Bay Area Spin-Off Company to Develop Drugs for Multiple Sclerosis and Alzheimer’s Disease
10/8/2019
The biotech company MedaRed, Inc. is founded on groundbreaking basic research from Gladstone Institutes, UC San Francisco, and UC San Diego.
-
Aimmune’s peanut allergy treatment is one-step closer to approval following strong support from the Allergenic Products Advisory Committee, which overwhelmingly recommended approval of Palforzia, the proposed trade name of the investigational oral treatment, AR101. -
Bristol-Myers Squibb's Opdivo Fails to Show Superiority to Bayer's Nexavar in Liver Cancer
6/24/2019
The drug failed to meet statistical significance for overall survival. However, the company is putting a positive spin on it, saying it showed a clear improvement trend in OS for patients treated with Opdivo compared to sorafenib. -
Researchers with the Hubrecht Institute in Utrecht, Netherlands and Radboud University in Nijmegen, Netherlands, recently developed a human model using organoids to evaluate the function of specific genes commonly mutated in liver cancer. -
The drug was approved as a second-line treatment for HCC patients who have an alpha-fetoprotein biomarker. -
Keytruda failed to show a statistical significance in overall survival and progression free survival in the Phase III trial. -
A New Culprit of Cognitive Decline in Alzheimer’s Disease
2/5/2019
It has long been known that patients with Alzheimer’s disease have abnormalities in the vast network of blood vessels in the brain. Some of these alterations may also contribute to age-related cognitive decline in people without dementia. However, the ways in which such vascular pathologies contribute to cognitive dysfunction have largely remained a mystery. Until now, that is.
-
Luckily, primary malignant liver tumors in children are rare. They account for only 1 to 2 percent of all childhood cancers. The most common treatment is surgery and chemotherapy. However, not all can be treated by surgery and sometimes they do not respond to chemotherapy. -
New Insights into the Aging Brain
11/12/2018
Gladstone scientists uncover new gatekeeper function of anti-aging molecule.
-
New Immunotherapy Targeting Blood-Clotting Protein Protects Multiple Sclerosis and Alzheimer’s Disease Models
10/15/2018
Gladstone researchers have stopped the detrimental effects of blood-brain barrier leaks.